Macromolecule Content

• Total Structure Weight: 23.09 kDa 
• Atom Count: 1626 
• Modelled Residue Count: 200 
• Deposited Residue Count: 200 
• Unique protein chains: 2

1G5J

COMPLEX OF BCL-XL WITH PEPTIDE FROM BAD

• DOI: 10.2210/pdb1G5J/pdb

• Classification: APOPTOSIS
• Organism(s): Homo sapiens
• Expression System: Escherichia coli
• Mutation(s): Yes 


• Deposited: 2000-11-01 Released: 2001-02-07 
• Deposition Author(s): Petros, A.M., Nettesheim, D.G., Wang, Y., Olejniczak, E.T., Meadows, R.P., Mack, J., Swift, K., Matayoshi, E.D., Zhang, H., Thompson, C.B., Fesik, S.W.

---

Experimental Data Snapshot

• Method: SOLUTION NMR
• Conformers Submitted: 1 

Literature

Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies.

Petros, A.M., Nettesheim, D.G., Wang, Y., Olejniczak, E.T., Meadows, R.P., Mack, J., Swift, K., Matayoshi, E.D., Zhang, H., Thompson, C.B., Fesik, S.W.

(2000) Protein Sci 9: 2528-2534

• PubMed: 11206074 
• DOI: 10.1110/ps.9.12.2528
• Primary Citation of Related Structures:  
  1G5J


• PubMed Abstract: 
  

The three-dimensional structure of the anti-apoptotic protein Bcl-xL complexed to a 25-residue peptide from the death promoting region of Bad was determined using NMR spectroscopy. Although the overall structure is similar to Bcl-xL bound to a 16-residue peptide from the Bak protein (Sattler et al., 1997), the Bad peptide forms additional interactions with Bcl-xL. However, based upon site-directed mutagenesis experiments, these additional contacts do not account for the increased affinity of the Bad 25-mer for Bcl-xL compared to the Bad 16-mer. Rather, the increased helix propensity of the Bad 25-mer is primarily responsible for its greater affinity for Bcl-xL. Based on this observation, a pair of 16-residue peptides were designed and synthesized that were predicted to have a high helix propensity while maintaining the interactions important for complexation with Bcl-xL. Both peptides showed an increase in helix propensity compared to the wild-type and exhibited an enhanced affinity for Bcl-xL.

---

Organizational Affiliation: 

Pharmaceutical Discovery Division, Abbott Laboratories, Abbott Park, Illinois 60064-6098, USA.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
APOPTOSIS REGULATOR BCL-X	A	175	Homo sapiens	Mutation(s): 0  Gene Names: BCLX, BCL2L1, BCL2L
Find proteins for Q07817 (Homo sapiens) Explore Q07817  Go to UniProtKB:  Q07817
NIH Common Fund Data Resources
PHAROS:  Q07817 GTEx:  ENSG00000171552

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details	Image
BAD PROTEIN	B	25	N/A	Mutation(s): 3
Find proteins for Q92934 (Homo sapiens) Explore Q92934  Go to UniProtKB:  Q92934
NIH Common Fund Data Resources
PHAROS:  Q92934 GTEx:  ENSG00000002330

Experimental Data & Validation

Experimental Data

• Method: SOLUTION NMR
• Conformers Submitted: 1 
• OLDERADO: 1G5J Olderado

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2000-11-01 
• Released Date: 2001-02-07 
Deposition Author(s): Petros, A.M., Nettesheim, D.G., Wang, Y., Olejniczak, E.T., Meadows, R.P., Mack, J., Swift, K., Matayoshi, E.D., Zhang, H., Thompson, C.B., Fesik, S.W.

Revision History  

• Version 1.0: 2001-02-07
  Type: Initial release
  
• Version 1.1: 2008-04-27
  Changes: Version format compliance
• Version 1.2: 2011-07-13
  Changes: Version format compliance